Kashiwagi, S., Yashiro, M., Takashima, T., Aomatsu, N., Ikeda, K., Ogawa, Y., . . . Hirakawa, K. (2011). Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: Usefulness of prognostic markers E-cadherin and Ki67. BioMed Central.
Chicago Stili AlıntıKashiwagi, Shinichiro, Masakazu Yashiro, Tsutomu Takashima, Naoki Aomatsu, Katsumi Ikeda, Yoshinari Ogawa, Tetsuro Ishikawa, ve Kosei Hirakawa. Advantages of Adjuvant Chemotherapy for Patients With Triple-negative Breast Cancer At Stage II: Usefulness of Prognostic Markers E-cadherin and Ki67. BioMed Central, 2011.
MLA AlıntıKashiwagi, Shinichiro, et al. Advantages of Adjuvant Chemotherapy for Patients With Triple-negative Breast Cancer At Stage II: Usefulness of Prognostic Markers E-cadherin and Ki67. BioMed Central, 2011.